| Description | MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity. |
| In vivo | MYLS22（10 mg/kg/天；肿瘤周围注射；每2天一次，连续14天）能够抑制小鼠的肿瘤生长。 |
| molecular weight | 443.52 |
| Molecular formula | C24H21N5O2S |
| CAS | 306959-01-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 45 mg/mL (101.46 mM), Sonication is recommended. |
| References | 1. Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8. |